Loading
Funders would publish how their spending compares with deaths and years of life lost per cancer, and commit to shift a fixed share of money each year towards the biggest gaps.
A burden-weighted formula sets a target share for each cancer type and each stage of the pipeline (prevention, detection, metastasis, delivery) using disability-adjusted life years and deaths from GLOBOCAN and the Global Burden of Disease study, adjusted by a tractability discount. Funders publish actual versus target and are held to a rebalancing rule of, for example, moving 10% of the discretionary portfolio per year towards under-funded areas. Analyses of NCI and UK spending have repeatedly shown lung, pancreatic, oesophageal, liver and stomach cancers receive far less per death than breast, leukaemia and prostate.
Shares International Agency for Research on Cancer (IARC / WHO), Funding follows fashion, not burden, Oesophageal cancer, Hepatocellular carcinoma.
Shares Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).
Shares A public dashboard of research money per death for every cancer, Funding follows fashion, not burden.
Shares Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).
Shares Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).
Shares International Agency for Research on Cancer (IARC / WHO), Oesophageal cancer, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer.
Shares International Agency for Research on Cancer (IARC / WHO), National Cancer Institute (NIH), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
Shares International Agency for Research on Cancer (IARC / WHO), Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).